5-Amino-1MQ vs Oxyntomodulin

Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms.

5-Amino-1-methylquinolinium (5-amino-1MQ) is a non-peptide small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation of nicotinamide using S-adenosyl methionine (SAM) as a methyl donor; NNMT is overexpressed in adipose tissue and has been identified as a metabolic regulator linking one-carbon metabolism, cellular methylation capacity, and adipogenesis. NNMT inhibition by 5-amino-1MQ is proposed to increase intracellular SAM and polyamine availability, shifting the cellular methylation balance in adipocytes toward suppression of adipogenesis and promotion of thermogenic gene expression; preclinical studies have examined effects on adipose tissue energy expenditure, systemic metabolism, and gut microbiome composition in diet-induced obesity mouse models. The best available indexed evidence is a preclinical study in diet-induced obese mice demonstrating that NNMT inhibition combined with caloric restriction altered microbiome composition and metabolic parameters; no human pharmacokinetic, safety, or efficacy data for 5-amino-1MQ has been published in any PubMed-indexed journal. 5-Amino-1MQ is a non-peptide research compound with no FDA approval or regulatory approval in any jurisdiction; it is not a peptide in the pharmacological sense and carries no human evidence base; all interest derives from preclinical metabolic data that has not been translated to human investigation. 5-Amino-1MQ dosage: No human clinical trial has established a dosing protocol for 5-Amino-1MQ. Preclinical research in rodent models has investigated this NNMT inhibitor at varying concentrations to assess metabolic effects. 5-Amino-1MQ is a research compound with no approved human dosing guidelines for any indication. Research protocols have explored oral and injectable delivery routes.

Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Oxyntomodulin is an endogenous 37-amino-acid proglucagon-derived peptide co-secreted with GLP-1 and PYY by intestinal L-cells in response to nutrient ingestion, distinguished from GLP-1 by a C-terminal octapeptide extension that enables dual agonism at both the GLP-1 receptor and the glucagon receptor, producing combined effects on appetite suppression, energy expenditure, and glucose homeostasis. GLP-1 receptor activation by oxyntomodulin reduces food intake through central satiety signaling, while concurrent glucagon receptor activation stimulates hepatic glucose production, thermogenesis in brown adipose tissue, and elevated energy expenditure — a combination that theoretically produces greater weight loss than GLP-1 receptor activation alone while the glucogenic and GLP-1 effects approximately offset each other's glycemic impact. A double-blind randomized controlled trial of subcutaneous oxyntomodulin in overweight and obese human subjects demonstrated significant body weight reduction versus placebo over a 4-week treatment period, establishing proof-of-concept for dual GLP-1/glucagon receptor co-agonism as a human anti-obesity mechanism and validating the pharmacological rationale for long-acting dual agonist drug development programs. Native oxyntomodulin has no FDA approval; its short plasma half-life from DPP-IV degradation precludes clinical development in its native form, and commercial research interest has shifted to stabilized long-acting dual agonist analogs such as cotadutide and retatrutide, which use this dual mechanism in engineered molecules with drug-like pharmacokinetics.